MedTrace Logo

Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC

NCT05386524 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2023-02-16

No results posted yet for this study

Summary

To evaluate the efficacy and safety of sintilimab and bevacizumab biosimilar combined with pegylated liposomal doxorubicin in pretreated metastatic triple-negative breast cancer

Conditions

Interventions

DRUG

sintilimab

sintilimab 200mg, ivgtt，d1

DRUG

bevacizumab biosimilar

bevacizumab biosimilar 15mg/kg，ivgtt d1

DRUG

pegylated liposomal doxorubicin

pegylated liposomal doxorubicin 30mg/m2 d1，q3w

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Biyun Wang, Prof · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-15
Primary Completion
2025-03-15
Completion
2025-03-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05386524 on ClinicalTrials.gov